Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RTA 402 Phase 3 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Diabetic Kidney Disease)

Trial Profile

RTA 402 Phase 3 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Diabetic Kidney Disease)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2018

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Acronyms AYAME
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 05 Jun 2018 New trial record
    • 04 Jun 2018 According to a Reata Pharmaceuticals media release, the study is expected to complete in Mar 2022.
    • 04 Jun 2018 Status changed from planning to recruiting, according to a Reata Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top